Skip to main content
SpringerLink
Log in

CANCER THERAPY

A treatment strategy for KRAS-driven tumors

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Studies in KRAS-mutant lung and pancreatic adenocarcinoma and in KRAS-amplified gastric carcinoma reveal that SHP2 inhibition augments the antitumor effect of MEK inhibitor treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: The effect of SHP2 on the RTK–KRAS–MAPK signaling pathway.

References

  1. Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Cancer Cell 25, 272–281 (2014).

    Article  PubMed  CAS  Google Scholar 

  2. Mainardi, S. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0023-9 (2018).

  3. Ruess, D. A. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0024-8 (2018).

  4. Wong, G. S. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0022-x (2018).

  5. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Patricelli, M. P. et al. Cancer Discov. 6, 316–329 (2016).

    Article  PubMed  CAS  Google Scholar 

  7. Lito, P. et al. Cancer Cell 25, 697–710 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Ran, H., Tsutsumi, R., Araki, T. & Neel, B. G. Cancer Cell 30, 194–196 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Chen, Y. N. et al. Nature 535, 148–152 (2016).

    Article  PubMed  CAS  Google Scholar 

  10. Dardaei, L. et al. Nat. Med. 24, 512–517 (2018).

    Article  PubMed  CAS  Google Scholar 

  11. Drosten, M. et al. EMBO J. 29, 1091–1104 (2010).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Science 351, 604–608 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

P.L. is supported by the National Institutes of Health (K08 CA191082-01A1), the Damon Runyon Cancer Research Foundation (Clinical Investigator Award), the LUNGevity Foundation (Career Development Award) and the V Foundation (Translational Grant).

Author information

Authors and Affiliations

  1. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Trang T. Mai & Piro Lito

  2. Weill Cornell Medical College, Cornell University, New York, NY, USA

    Piro Lito

Authors
  1. Trang T. Mai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Piro Lito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Piro Lito.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mai, T.T., Lito, P. A treatment strategy for KRAS-driven tumors. Nat Med 24, 902–904 (2018). https://doi.org/10.1038/s41591-018-0111-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-018-0111-x

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation